Global, regional, and national burden of ovarian cancer, 1990-2021, and projections to 2050: a cross-sectional analysis of the Global Burden of Disease Study 2021.

Int J Surg · 2026 · PMC12825783 · PMID 40928736

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In the PAOLA-1 trial, maintenance therapy combining olaparib and bevacizumab showed a trend toward improved overall survival in patients with BRCA mutations and HRD [ 37 , 38 ] .

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.